FDA Cleared Inhaled Stem Cell Study for COPD
The trial will evaluate a novel nebulized therapy designed to help repair damaged lung tissue in adults.
Updated on Oct. 9, 2026 in Asthma
Live Poll
Do you trust current regulatory processes to ensure new experimental medical treatments are safe?
In September 2026, the FDA issued a Study May Proceed notification for a phase 1b clinical trial investigating blood-derived allogeneic Small Mobile Stem (SMS) cells. The experimental therapy, which is administered via nebulizer, is intended to treat Chronic Obstructive Pulmonary Disease (COPD).
Why it matters
Currently, there are no FDA-approved regenerative medicine therapies for COPD, making this investigation a potential shift in how clinicians manage long-term lung tissue damage. The study explores a new approach of stimulating existing repair pathways rather than replacing cells.
In an initial Australian study, the first cohort completed 28 days of safety monitoring with no therapy-related adverse events reported. This preliminary finding supports moving toward a phase 1b study in the United States to further evaluate the therapy.
The players
SMSbiotech
A biotechnology company focused on developing blood-derived stem cell therapies for respiratory conditions.
FDA
The United States government agency responsible for overseeing the safety and efficacy of new medical therapies.
The details
The SMS cells are engineered to bind to lung tissue, where they influence gene activity and cellular proliferation to promote natural healing. Because the therapy is delivered via a nebulized inhalation, researchers must ensure the cells maintain their viability and potency after the nebulization process.
Timeline
October 1, 2025: AABB Cell and Gene Therapy Standards for Pharmacy became effective.
September 2026: FDA issued a Study May Proceed notification for the trial.
Health Landscape
This research trial is part of an emerging field of regenerative medicine aimed at managing progressive respiratory conditions. It follows the adoption of the AABB Cell and Gene Therapy Standards for Pharmacy, which guide the safe handling of advanced biologics.
This study is currently in an early phase and is not a treatment available to the public. If you live with COPD, it is worth discussing the current standard of care and any available clinical trials with your pulmonologist.
The takeaway
Regenerative therapies for lung disease are in the early stages of human clinical trials and are not yet approved for clinical use. Patients interested in emerging treatment modalities should keep track of their lung function metrics and consult with their physician about local research opportunities.
Further reading
For more information on managing chronic respiratory conditions, visit our Asthma section.
More information
View the official SMSbiotech COPD program FDA clearance announcement.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust current regulatory processes to ensure new experimental medical treatments are safe?
